Fig 1: Immune cell infiltration in COAD. (A) Proportion of immune cells in COAD patients estimated by the CIBERSORT algorithm in TCGA data. (B) Differences in the level of immune cell infiltration between COAD and controls and between high-group and low-group. Red is high infiltration and blue is low infiltration. (C) Radar chart showing the correlation between DLL3 and immune cells in COAD. (D) Differential expression of DLL3 between COAD and control in TCGA, GSE39582 and GSE44076 data. ***p < 0.001. (E) ROC curves of DLL3 in TCGA, GSE39582 and GSE44076 datasets predicting COAD.
Fig 2: Predictive evaluation of characteristic genes for prognosis of COAD patients. (A) Risk score model, patient survival status and expression of 10 signature genes in TCGA data. (B) A column line graph was created to visualize the effect of the expression of the signature genes and the risk score model on patient prognosis. (C) Corrected curves of 3-year and 5-year OS of COAD patients in the TCGA dataset. (D) Time-dependent ROC curves for median risk scores. (E) Cox regression analysis of the signature gene and DLL3.
Fig 3: Differentially expressed genes between colon adenocarcinoma (COAD) and control. (A) COAD samples from TCGA data were divided into high- and low-expression group according to the best cutoff value of DLL3 expression. (B) K-M curves demonstrating the difference in overall survival probability of COAD patients between high- and low-expression group. (C) Volcano plot of DEGs between COAD and control in TCGA data. (D) Statistical histogram of the four groups of DEGs. (E) Intersection of the four groups with up- or downregulated DEGs. (The bestDEG_up refers to the upregulated genes in the 8,073 differentially expressed genes.) (F) Cumulative distribution plot and the log2 fold change plot (G) showing the similarity of intersecting gene expressions.
Fig 4: Gene set enrichment analysis (GSEA) results for DLL3 high-vs. low-expression group and COAD tumor vs. normal in TCGA. (A) AMPK signaling pathway was suppressed in DLL3 high-expression group and tumor group. (B) Mitophagy-animal was suppressed in DLL3 high-expression group and tumor group.
Fig 5: Expression and survival analysis of DLL3. (A) IHC staining of DLL3 in COAD samples (×400 magnification). Case 1: DLL3 expression in adjecent and tumor tissues. Case 2: DLL3 expression primary and metastatic lesion. (B) Paired analysis of DLL3 expression in normal and tumor tissues. (C) Paired analysis of DLL3 expression in cancer and metastatic lesion. (D) Disease stage and DLL3 (E) T stage and DLL3 (F) M stage and DLL3 (G) Kaplan–Meier survival analysis of COAD patients with OS based on DLL3 expression.
Supplier Page from Abcam for Anti-DLL3 antibody [EPR22592-18]